Travelers Vaccines Comprehensive Study by Type (Mono Vaccines, Combination Vaccines), Application (Tourists, Students, Workers, Others), Disease (Meningococcal Vaccine, Japanese Encephalitis Vaccine, Yellow Fever Vaccine, Hepatitis Vaccine, Cholera Vaccine, Others) Players and Region - Global Market Outlook to 2026

Travelers Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Travelers Vaccines Market?

Travelers vaccines, also known as travel immunizations are shots travelers can get before visiting certain areas of the world that help protect them from serious illnesses. The body responds to the vaccination by making antibodies that will protect you if you are exposed to the disease in the future. Travelers' vaccines are effective, and safe ways to help protect travelers from bringing home more than they bargained for, this is projected the growth of the market in the forecast period.

The market study is being classified by Type (Mono Vaccines and Combination Vaccines), by Application (Tourists, Students, Workers and Others) and major geographies with country level break-up.

GlaxoSmithKline plc (United Kingdom), Sanofi Pasteur (France), Merck & Co., Inc. (United States), Pfizer (United States), China National Pharmaceutical Group (China), Sanofi Pasteur MSD (France), Serum Institute of India (India) and Biokangtai (China) are some of the key players profiled in the study.

The Players having a strong hold in the market are GlaxoSmithKline plc, Sanofi Pasteur, and Merck & Co., Inc.. Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Travelers Vaccines market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Travelers Vaccines market by Type, Application and Region.

On the basis of geography, the market of Travelers Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Preferences for Outsourcing of Vaccine in the Under Developing and Developed Countries
  • Extreme Low Risk of Serious Side Effects on the Fetus

Market Trend
  • Increasing Globalization and International Travelling

Restraints
  • Strict Norms and Regulatory Pathway

Opportunities
  • Various Government and Nonprofit Organization are taking Educational & Awareness Programs Travelers Vaccines

Challenges
  • High-cost Associated with Vaccine Transportation, Storage, and New Vaccine Discovery





Key Target Audience
Travelers Vaccines Providers, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors and Other

Report Objectives / Segmentation Covered

By Type
  • Mono Vaccines
  • Combination Vaccines
By Application
  • Tourists
  • Students
  • Workers
  • Others
By Disease
  • Meningococcal Vaccine
  • Japanese Encephalitis Vaccine
  • Yellow Fever Vaccine
  • Hepatitis Vaccine
  • Cholera Vaccine
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Preferences for Outsourcing of Vaccine in the Under Developing and Developed Countries
      • 3.2.2. Extreme Low Risk of Serious Side Effects on the Fetus
    • 3.3. Market Challenges
      • 3.3.1. High-cost Associated with Vaccine Transportation, Storage, and New Vaccine Discovery
    • 3.4. Market Trends
      • 3.4.1. Increasing Globalization and International Travelling
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Travelers Vaccines, by Type, Application, Disease and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Travelers Vaccines (Value)
      • 5.2.1. Global Travelers Vaccines by: Type (Value)
        • 5.2.1.1. Mono Vaccines
        • 5.2.1.2. Combination Vaccines
      • 5.2.2. Global Travelers Vaccines by: Application (Value)
        • 5.2.2.1. Tourists
        • 5.2.2.2. Students
        • 5.2.2.3. Workers
        • 5.2.2.4. Others
      • 5.2.3. Global Travelers Vaccines by: Disease (Value)
        • 5.2.3.1. Meningococcal Vaccine
        • 5.2.3.2. Japanese Encephalitis Vaccine
        • 5.2.3.3. Yellow Fever Vaccine
        • 5.2.3.4. Hepatitis Vaccine
        • 5.2.3.5. Cholera Vaccine
        • 5.2.3.6. Others
      • 5.2.4. Global Travelers Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Travelers Vaccines (Price)
      • 5.3.1. Global Travelers Vaccines by: Type (Price)
  • 6. Travelers Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi Pasteur (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. China National Pharmaceutical Group (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi Pasteur MSD (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Serum Institute of India (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biokangtai (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Travelers Vaccines Sale, by Type, Application, Disease and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Travelers Vaccines (Value)
      • 7.2.1. Global Travelers Vaccines by: Type (Value)
        • 7.2.1.1. Mono Vaccines
        • 7.2.1.2. Combination Vaccines
      • 7.2.2. Global Travelers Vaccines by: Application (Value)
        • 7.2.2.1. Tourists
        • 7.2.2.2. Students
        • 7.2.2.3. Workers
        • 7.2.2.4. Others
      • 7.2.3. Global Travelers Vaccines by: Disease (Value)
        • 7.2.3.1. Meningococcal Vaccine
        • 7.2.3.2. Japanese Encephalitis Vaccine
        • 7.2.3.3. Yellow Fever Vaccine
        • 7.2.3.4. Hepatitis Vaccine
        • 7.2.3.5. Cholera Vaccine
        • 7.2.3.6. Others
      • 7.2.4. Global Travelers Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Travelers Vaccines (Price)
      • 7.3.1. Global Travelers Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Travelers Vaccines: by Type(USD Million)
  • Table 2. Travelers Vaccines Mono Vaccines , by Region USD Million (2015-2020)
  • Table 3. Travelers Vaccines Combination Vaccines , by Region USD Million (2015-2020)
  • Table 4. Travelers Vaccines: by Application(USD Million)
  • Table 5. Travelers Vaccines Tourists , by Region USD Million (2015-2020)
  • Table 6. Travelers Vaccines Students , by Region USD Million (2015-2020)
  • Table 7. Travelers Vaccines Workers , by Region USD Million (2015-2020)
  • Table 8. Travelers Vaccines Others , by Region USD Million (2015-2020)
  • Table 9. Travelers Vaccines: by Disease(USD Million)
  • Table 10. Travelers Vaccines Meningococcal Vaccine , by Region USD Million (2015-2020)
  • Table 11. Travelers Vaccines Japanese Encephalitis Vaccine , by Region USD Million (2015-2020)
  • Table 12. Travelers Vaccines Yellow Fever Vaccine , by Region USD Million (2015-2020)
  • Table 13. Travelers Vaccines Hepatitis Vaccine , by Region USD Million (2015-2020)
  • Table 14. Travelers Vaccines Cholera Vaccine , by Region USD Million (2015-2020)
  • Table 15. Travelers Vaccines Others , by Region USD Million (2015-2020)
  • Table 16. South America Travelers Vaccines, by Country USD Million (2015-2020)
  • Table 17. South America Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 18. South America Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 19. South America Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 20. Brazil Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 21. Brazil Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 22. Brazil Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 23. Argentina Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 24. Argentina Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 25. Argentina Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 26. Rest of South America Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 29. Asia Pacific Travelers Vaccines, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 32. Asia Pacific Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 33. China Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 34. China Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 35. China Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 36. Japan Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 37. Japan Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 38. Japan Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 39. India Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 40. India Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 41. India Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 42. South Korea Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 43. South Korea Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 44. South Korea Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 45. Taiwan Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 46. Taiwan Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 47. Taiwan Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 48. Australia Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 49. Australia Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 50. Australia Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 54. Europe Travelers Vaccines, by Country USD Million (2015-2020)
  • Table 55. Europe Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 56. Europe Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 57. Europe Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 58. Germany Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 59. Germany Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 60. Germany Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 61. France Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 62. France Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 63. France Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 64. Italy Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 65. Italy Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 66. Italy Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 67. United Kingdom Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 69. United Kingdom Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 70. Netherlands Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 71. Netherlands Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 72. Netherlands Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 73. Rest of Europe Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 75. Rest of Europe Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 76. MEA Travelers Vaccines, by Country USD Million (2015-2020)
  • Table 77. MEA Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 78. MEA Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 79. MEA Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 80. Middle East Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 81. Middle East Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 82. Middle East Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 83. Africa Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 84. Africa Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 85. Africa Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 86. North America Travelers Vaccines, by Country USD Million (2015-2020)
  • Table 87. North America Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 88. North America Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 89. North America Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 90. United States Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 91. United States Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 92. United States Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 93. Canada Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 94. Canada Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 95. Canada Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 96. Mexico Travelers Vaccines, by Type USD Million (2015-2020)
  • Table 97. Mexico Travelers Vaccines, by Application USD Million (2015-2020)
  • Table 98. Mexico Travelers Vaccines, by Disease USD Million (2015-2020)
  • Table 99. Travelers Vaccines: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Travelers Vaccines: by Type(USD Million)
  • Table 109. Travelers Vaccines Mono Vaccines , by Region USD Million (2021-2026)
  • Table 110. Travelers Vaccines Combination Vaccines , by Region USD Million (2021-2026)
  • Table 111. Travelers Vaccines: by Application(USD Million)
  • Table 112. Travelers Vaccines Tourists , by Region USD Million (2021-2026)
  • Table 113. Travelers Vaccines Students , by Region USD Million (2021-2026)
  • Table 114. Travelers Vaccines Workers , by Region USD Million (2021-2026)
  • Table 115. Travelers Vaccines Others , by Region USD Million (2021-2026)
  • Table 116. Travelers Vaccines: by Disease(USD Million)
  • Table 117. Travelers Vaccines Meningococcal Vaccine , by Region USD Million (2021-2026)
  • Table 118. Travelers Vaccines Japanese Encephalitis Vaccine , by Region USD Million (2021-2026)
  • Table 119. Travelers Vaccines Yellow Fever Vaccine , by Region USD Million (2021-2026)
  • Table 120. Travelers Vaccines Hepatitis Vaccine , by Region USD Million (2021-2026)
  • Table 121. Travelers Vaccines Cholera Vaccine , by Region USD Million (2021-2026)
  • Table 122. Travelers Vaccines Others , by Region USD Million (2021-2026)
  • Table 123. South America Travelers Vaccines, by Country USD Million (2021-2026)
  • Table 124. South America Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 125. South America Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 126. South America Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 127. Brazil Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 128. Brazil Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 129. Brazil Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 130. Argentina Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 131. Argentina Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 132. Argentina Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 133. Rest of South America Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 134. Rest of South America Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 135. Rest of South America Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 136. Asia Pacific Travelers Vaccines, by Country USD Million (2021-2026)
  • Table 137. Asia Pacific Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 138. Asia Pacific Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 139. Asia Pacific Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 140. China Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 141. China Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 142. China Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 143. Japan Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 144. Japan Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 145. Japan Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 146. India Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 147. India Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 148. India Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 149. South Korea Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 150. South Korea Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 151. South Korea Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 152. Taiwan Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 153. Taiwan Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 154. Taiwan Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 155. Australia Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 156. Australia Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 157. Australia Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 161. Europe Travelers Vaccines, by Country USD Million (2021-2026)
  • Table 162. Europe Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 163. Europe Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 164. Europe Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 165. Germany Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 166. Germany Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 167. Germany Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 168. France Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 169. France Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 170. France Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 171. Italy Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 172. Italy Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 173. Italy Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 174. United Kingdom Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 175. United Kingdom Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 176. United Kingdom Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 177. Netherlands Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 178. Netherlands Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 179. Netherlands Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 180. Rest of Europe Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 181. Rest of Europe Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 182. Rest of Europe Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 183. MEA Travelers Vaccines, by Country USD Million (2021-2026)
  • Table 184. MEA Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 185. MEA Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 186. MEA Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 187. Middle East Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 188. Middle East Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 189. Middle East Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 190. Africa Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 191. Africa Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 192. Africa Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 193. North America Travelers Vaccines, by Country USD Million (2021-2026)
  • Table 194. North America Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 195. North America Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 196. North America Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 197. United States Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 198. United States Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 199. United States Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 200. Canada Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 201. Canada Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 202. Canada Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 203. Mexico Travelers Vaccines, by Type USD Million (2021-2026)
  • Table 204. Mexico Travelers Vaccines, by Application USD Million (2021-2026)
  • Table 205. Mexico Travelers Vaccines, by Disease USD Million (2021-2026)
  • Table 206. Travelers Vaccines: by Type(USD/Units)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Travelers Vaccines: by Type USD Million (2015-2020)
  • Figure 5. Global Travelers Vaccines: by Application USD Million (2015-2020)
  • Figure 6. Global Travelers Vaccines: by Disease USD Million (2015-2020)
  • Figure 7. South America Travelers Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Travelers Vaccines Share (%), by Country
  • Figure 9. Europe Travelers Vaccines Share (%), by Country
  • Figure 10. MEA Travelers Vaccines Share (%), by Country
  • Figure 11. North America Travelers Vaccines Share (%), by Country
  • Figure 12. Global Travelers Vaccines: by Type USD/Units (2015-2020)
  • Figure 13. Global Travelers Vaccines share by Players 2020 (%)
  • Figure 14. Global Travelers Vaccines share by Players (Top 3) 2020(%)
  • Figure 15. Global Travelers Vaccines share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi Pasteur (France) Revenue: by Geography 2020
  • Figure 21. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (United States) Revenue: by Geography 2020
  • Figure 25. China National Pharmaceutical Group (China) Revenue, Net Income and Gross profit
  • Figure 26. China National Pharmaceutical Group (China) Revenue: by Geography 2020
  • Figure 27. Sanofi Pasteur MSD (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi Pasteur MSD (France) Revenue: by Geography 2020
  • Figure 29. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 30. Serum Institute of India (India) Revenue: by Geography 2020
  • Figure 31. Biokangtai (China) Revenue, Net Income and Gross profit
  • Figure 32. Biokangtai (China) Revenue: by Geography 2020
  • Figure 33. Global Travelers Vaccines: by Type USD Million (2021-2026)
  • Figure 34. Global Travelers Vaccines: by Application USD Million (2021-2026)
  • Figure 35. Global Travelers Vaccines: by Disease USD Million (2021-2026)
  • Figure 36. South America Travelers Vaccines Share (%), by Country
  • Figure 37. Asia Pacific Travelers Vaccines Share (%), by Country
  • Figure 38. Europe Travelers Vaccines Share (%), by Country
  • Figure 39. MEA Travelers Vaccines Share (%), by Country
  • Figure 40. North America Travelers Vaccines Share (%), by Country
  • Figure 41. Global Travelers Vaccines: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Sanofi Pasteur (France)
  • Merck & Co., Inc. (United States)
  • Pfizer (United States)
  • China National Pharmaceutical Group (China)
  • Sanofi Pasteur MSD (France)
  • Serum Institute of India (India)
  • Biokangtai (China)
Select User Access Type

Key Highlights of Report


Sep 2021 206 Pages 83 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Preferences for Outsourcing of Vaccine in the Under Developing and Developed Countries " is seen as one of major growth factors of Travelers Vaccines Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
European will lead Travelers Vaccines Market in coming years.

Know More About Global Travelers Vaccines research Report?